Minaxi P. Jhawer, MD

Insurances Accepted

Below is a list of the insurance plans that your provider participates in. It is very important that you contact your insurance company prior to receiving services or care. Each health insurance plan is different and some provide different levels of coverage: only your health insurance plan can provide complete information regarding your coverage and potential out-of-pocket costs.

About Minaxi Jhawer

Dr. Jhawer is chief of hematology/oncology. She is board certified in internal medicine, medical oncology, and hematology and specializes in cancers of the esophagus, stomach, small bowel, liver and bile ducts (hepatobiliary tract), pancreas, colon, and rectum. Dr. Jhawer completed postdoctoral fellowship training at Johns Hopkins University. After her residency and fellowship at Albert Einstein College of Medicine, she served on the gastrointestinal medical oncology faculty at Memorial Sloan Kettering Cancer Center. She developed and co-led EHMC's disease management team in gastroenterology and hepatobiliary cancer. She co-leads the multidisciplinary cancer conferences for patients diagnosed with GI cancer.

Dr. Jhawer collaborates with colleagues from New York City hospitals on caring for oncology patients and on clinical trials. She has been a principal investigator on many clinical trials and has presented her work at national conferences and been published in peer-reviewed journals. Dr. Jhawer is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Association for Cancer Research. She was recently appointed to the Clinical Practice Guidelines Committee of the American Society of Clinical Oncology. Dr. Jhawer is active in medical education and community outreach programs. She is involved in development of the survivorship plan, palliative care in the outpatient setting, and integrative medicine atEnglewood Health's Graf Center for Integrative Medicine.

Honors & Awards

2020, 2019, 2017: Bergen Magazine Top Doctors

2020-2016: Castle Connolly Top Doctors New York Metro Area

2019: Exceptional Women in Medicine

2019-2017: Jersey's Best: Top Doctors for Cancer

2019-2015: Jersey's Best Magazine Top Doctors

2018, 2017, 2015: New York Magazine Best Doctors

2018: New Jersey Monthly Magazine Top Doctor

2017: Americas Most Honored Top 1% Professionals

2015: Life and Living Show- Interview 5/20/15

2015: 201 Magazine Top Doctors-Top 20 People to Watch in Health Care

Professional Memberships

American Society of Clinical Oncology

American Society of Hematology

American Medical Association

American Association for Cancer Research

Bergen Indian Medical Association

Committees and Leadership Positions

Chief, Hematology/Oncology

2017 - 2020: Member, American Society of Clinical Oncology Clinical Practice Guidelines Committee

2017: Elected to Medical Executive Committee

2016 - present: Bylaws Committee

2014 - present: Advisory Board for Integrative Medicine Department

2014 - present: Medical Advisory Board for Kula for Karma

Co-Leader for Upper, Lower GI and Hepatobiliary Tumor Board and DMT

Established Funding for Complementary Yoga Program for Englewood Hospital Cancer Patients and Their Caregivers

Survivorship Program for Patients with Curable Cancers

Established Pain and Palliative Consultation and Care in the Outpatient Oncology Setting

Global Health and Community Health Activities

Korean /Asian population screening for GI cancers

Publications

Klute KA, Brouwer J, Jhawer M, et al. Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: A multicenter analysis. Eur J Cancer. 2016 Aug;63:189-200

Shah MA, Jhawer M, Ilson D, Lekowitz RA et al. Phase II study of modified docetaxel, cisplatin,and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011 Mar 1;29(7):868-74

Wilson AK, Cheuh AC, Togel L, Corner GA, Ahmed N, Goel S, Byun DS, Nasser S, Houston MA, Jhawer M et al. Apoptotic sensitivity of colon cancer cell lines to histone deacetylase inhibitors is mediated by sp1/sp3 activated transcriptional program involving immediate early gene induction. Cancer Res 2010 Jan 15; 70(2):609-20

Yuan Z, Shin J, Wilson A, Goel S, Ahmed N, Dopeso H, Jhawer M, et al. An A13 repeat within the 3-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression. Cancer Res 2009 Oct 1;69(19):7811-8

Jhawer M, Coit D, Brennan M, Qin L, Gonen M, Klimstra D, Tang L, Kelsen D, Shah MA. Perineural invasion following preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation. Am J Clin Oncol. 2009 Aug;32(4):356-62

Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH et al. PIK3CA mutation/ PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res.2008 Mar 15;68(6):1953-61

Jhawer M, Kelsen D, Shah M. Incorporation of biologic therapies in the management of gastroesophageal cancers. Gastrointest Cancer Res. 2007 Mar; 1(2 suppl): S22-9

Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, et al. Phase II Trial of Nolatrexed Dihydrochloride [ThymitaqTM, AG 337] in Patients with Advanced Hepatocellular Carcinoma. Investigational New Drugs 2007 Feb 25(1):85-94

Jhawer M, Mani S, Lefkopoulou M, Hahn R, Harris J, et al. Phase II study of Mitomycin-C, Adriamycin, Cisplatin and Bleomycin-CCNU in patients with advanced anal canal cancer: An ECOG study, E 7282. Investigational New Drugs 2006 Sep; 24(5):447-54

Goel S, Jhawer M, Sparano J, Mani S, et al Phase I clinical trial of the combination of irinotecan and oral capecitabine in patients with solid malignancies. Am J Clin Oncol. 2002 Oct; 25(5):528-34

For a full listing of Dr. Jhawer's publications, please visit PubMed.gov